Piper Sandler Reiterates Overweight on Skye Bioscience, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating on Skye Bioscience (OTC:SKYE) and increased the price target from $12 to $20.
March 14, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating on Skye Bioscience and raised the price target from $12 to $20.
The reiteration of an Overweight rating combined with a significant increase in the price target from $12 to $20 by a reputable analyst firm like Piper Sandler is likely to instill confidence among investors and could lead to a short-term increase in SKYE's stock price. The substantial raise in the price target reflects a positive outlook on the company's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100